Skip to content

An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel

An Observational Study to Evaluate the Safety and Effectiveness of Radiotherapy for Localized T1-T2 Prostate Cancer in China After Injection of SpaceOAR Hydrogel

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05735652
Enrollment
14
Registered
2023-02-21
Start date
2022-11-03
Completion date
2024-08-21
Last updated
2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.

Detailed description

This study protocol is for the second part of SpaceOAR real world study in which long term follow-up visits will be performed (up to 1 year) outside Boao Medical Tourism Pilot Zone. The SpaceOAR real world study is a retrospective and prospective, single arm, observational study (Ptotocol of SpaceOAR RWS Windchill#: 92743236). Subjects with localized T1-T2 prostate cancer who have already been injected with the SpaceOAR and have received radiotherapy or will receive radiotherapy will be enrolled, and clinical data related to radiotherapy will be collected. For subjects who have already completed radiotherapy before study kick-off, clinical data will be collected retrospectively, such as data related to radiotherapy, AE (if any) and MRI (if any). Follow up vist will be completed if applicable. For subjects who receive therapy after study kick-off, follow up visits at 2 weeks, 6weeks, 3 months and 10 months after radiotherapy will be scheduled to assess bowel, urinary and sexual function and quality of life.

Interventions

DEVICESpaceOAR Hydrogel

The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum

Sponsors

Boston Scientific Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* Subjects have provided the written informed consent, are willing to participate in clinical data collection and willing to comply with study procedure. (for subjects enrolled prospectively) * Subjects must have been pathologically confirmed prostate cancer with clinical stage T1-T2, and have been treated with Space OAR Hydrogel, and have received or will receive radiotherapy.

Exclusion criteria

* All subjects have received radiotherapy or will receive radiotherapy, who have injected with SpaceOAR hydrogel in Boao Medical Pilot Zone. * There is no specific

Design outcomes

Primary

MeasureTime frameDescription
Change of Dose Rectum Volume Receiving Radiation Between Radiotherapy Plannings Pre and Post SpaceOAR Hydrogel Injection.Post injection gel surgery 1-10 daysChange of dose rectum volume receiving radiation,which is measured by Dose-volume histogram in radiotherapy planning pre and post SpaceOAR hydrogel injection radiotherpy planning is made based on CT simulation scans.

Secondary

MeasureTime frameDescription
Urinary, Bowel and Sexual Function Assessment ScoreAfter the completion of radiotherapy, the month 3 Expanded Prostate Cancer Index Composite (EPIC)-26 score was compared to the baseline EPIC-26 score.Descrpition of change of urinary, bowel and Sexual function assessment score, which are measured by Expanded Prostate cancer Index Composite (EPIC)-26. EPIC-26 is short form version to measure health related quality of life among men with prostate cancer, which contains 26 item and 5 domains : Urinary Incontinence, Urinary irritative/Obstructive, Bowel, Sexual, and Hormonal. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly from 0 score to 100 scores, with higher scores representing better.
Quality of Life Was Measured by EQ-5D-5L Scale(the Five-level Version of the EuroQol 5-Dimension Scale)After the completion of radiotherapy, the month 3 EQ-5D-5L scale(the five-level version of the EuroQol 5-Dimension scale) score was compared to the baseline EQ-5D-5L scale score.Frequencies and proportions of responses in five dimension (Mobility, Anxiety/Depression, Pain/Discomfort, Usual Activities and Self-Care) and different levels will be tabulated, which was measured by EQ-5D-5L scale(the five-level version of the EuroQol 5-Dimension scale).The minimum value and maximum value of EQ VAS (EQ visual analogue scale) are from 0 score to100 scores, which a higher value means a beter outcome.
The Distance Between Prostate and RectumAfter the completion of radiotherapy, the weeks 6 the distance between prostate and rectum measured by MRI was compared to the baseline the distance between prostate and rectum measured by MRI.The distance between the posterior prostatic capsule and anterior rectal wall is measured on the axial image slice closest to halfway between apex and base, from posterior edge of prostate to inner rectal wall via MRI.
the Distance Between the Prostate and RectumAfter the completion of radiotherapy, the month 10 the distance between prostate and rectum measured by MRI was compared to the baseline the distance between prostate and rectum measured by MRI.The presence of SpaceOAR hydrogel between prostate and rectum is evaluated by MRI via distance indirectly.
Adverse Event Related to SpaceOAR Hydrogel (Safety)Through the entire study phase until 10 months after the completion of radiotherapy.The relationship of AE /ADE/SAE/SADE/UADEs will be assessed by investigators.

Countries

China

Participant flow

Recruitment details

Potential subjects for this study are patients with localized prostate cancer enrolled in the SpaceOAR Hainan Real World Study (U0720) who have been treated with SpaceOAR hydrogel at a hospital in the Boao Lecheng Medical Pilot Area in Hainan and have received or will receive radiation therapy at the study center.

Participants by arm

ArmCount
Single Arm Obsevational Study Total 14 Cases
This observational single arm study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy. SpaceOAR Hydrogel: The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum.
14
Total14

Baseline characteristics

CharacteristicSingle Arm Obsevational Study Total 14 Cases
Age, Continuous74.1 years
STANDARD_DEVIATION 7.9
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
14 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Sex/Gender, Customized
Count of Participants
Female
0 Participants
Sex/Gender, Customized
Count of Participants
Male
14 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 14
other
Total, other adverse events
4 / 14
serious
Total, serious adverse events
1 / 14

Outcome results

Primary

Change of Dose Rectum Volume Receiving Radiation Between Radiotherapy Plannings Pre and Post SpaceOAR Hydrogel Injection.

Change of dose rectum volume receiving radiation,which is measured by Dose-volume histogram in radiotherapy planning pre and post SpaceOAR hydrogel injection radiotherpy planning is made based on CT simulation scans.

Time frame: Post injection gel surgery 1-10 days

Population: Potential subjects for this study are patients with localized prostate cancer enrolled in the SpaceOAR Hainan Real World Study (U0720) who have been treated with SpaceOAR hydrogel at a hospital in the Boao Licheng Medical Pilot Area in Hainan and have received or will receive radiation therapy at the study center.

ArmMeasureGroupValue (MEAN)Dispersion
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelChange of Dose Rectum Volume Receiving Radiation Between Radiotherapy Plannings Pre and Post SpaceOAR Hydrogel Injection.Rectum wall V37Gy (cc)2.4 ccStandard Deviation 2.8
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelChange of Dose Rectum Volume Receiving Radiation Between Radiotherapy Plannings Pre and Post SpaceOAR Hydrogel Injection.Rectum wall V46Gy (cc)2.7 ccStandard Deviation 2.5
Secondary

Adverse Event Related to SpaceOAR Hydrogel (Safety)

The relationship of AE /ADE/SAE/SADE/UADEs will be assessed by investigators.

Time frame: Through the entire study phase until 10 months after the completion of radiotherapy.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelAdverse Event Related to SpaceOAR Hydrogel (Safety)0 Participants
Secondary

Quality of Life Was Measured by EQ-5D-5L Scale(the Five-level Version of the EuroQol 5-Dimension Scale)

Frequencies and proportions of responses in five dimension (Mobility, Anxiety/Depression, Pain/Discomfort, Usual Activities and Self-Care) and different levels will be tabulated, which was measured by EQ-5D-5L scale(the five-level version of the EuroQol 5-Dimension scale).The minimum value and maximum value of EQ VAS (EQ visual analogue scale) are from 0 score to100 scores, which a higher value means a beter outcome.

Time frame: After the completion of radiotherapy, the month 3 EQ-5D-5L scale(the five-level version of the EuroQol 5-Dimension scale) score was compared to the baseline EQ-5D-5L scale score.

Population: For subjects who have already completed radiotherapy before study kick-off, clinical data will be collected retrospectively, such as data related to radiotherapy, AE (if any) and MRI (if any), and follow up will be performed, if applicable.~For subjects who receive therapy after study kick-off, radiotherapy relevant clinical data will be collected, and follow up visits after radiotherapy will be scheduled to assess urinary, bowel, sexual functions and AE

ArmMeasureValue (MEAN)Dispersion
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelQuality of Life Was Measured by EQ-5D-5L Scale(the Five-level Version of the EuroQol 5-Dimension Scale)1.0 score on a scaleStandard Deviation 0
Secondary

The Distance Between Prostate and Rectum

The distance between the posterior prostatic capsule and anterior rectal wall is measured on the axial image slice closest to halfway between apex and base, from posterior edge of prostate to inner rectal wall via MRI.

Time frame: After the completion of radiotherapy, the weeks 6 the distance between prostate and rectum measured by MRI was compared to the baseline the distance between prostate and rectum measured by MRI.

ArmMeasureValue (MEAN)Dispersion
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelThe Distance Between Prostate and Rectum5.4 mmStandard Deviation 3.8
Secondary

the Distance Between the Prostate and Rectum

The presence of SpaceOAR hydrogel between prostate and rectum is evaluated by MRI via distance indirectly.

Time frame: After the completion of radiotherapy, the month 10 the distance between prostate and rectum measured by MRI was compared to the baseline the distance between prostate and rectum measured by MRI.

ArmMeasureValue (MEAN)Dispersion
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR Hydrogelthe Distance Between the Prostate and Rectum2.0 mmStandard Deviation 1.2
Secondary

Urinary, Bowel and Sexual Function Assessment Score

Descrpition of change of urinary, bowel and Sexual function assessment score, which are measured by Expanded Prostate cancer Index Composite (EPIC)-26. EPIC-26 is short form version to measure health related quality of life among men with prostate cancer, which contains 26 item and 5 domains : Urinary Incontinence, Urinary irritative/Obstructive, Bowel, Sexual, and Hormonal. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly from 0 score to 100 scores, with higher scores representing better.

Time frame: After the completion of radiotherapy, the month 3 Expanded Prostate Cancer Index Composite (EPIC)-26 score was compared to the baseline EPIC-26 score.

ArmMeasureGroupValue (MEAN)Dispersion
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelUrinary, Bowel and Sexual Function Assessment ScoreBowel function99.4 score on a scaleStandard Deviation 1.5
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelUrinary, Bowel and Sexual Function Assessment ScoreUrinary Incontinence92.9 score on a scaleStandard Deviation 12.7
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelUrinary, Bowel and Sexual Function Assessment ScoreUrinary rritative /Obstructive96.0 score on a scaleStandard Deviation 5.3
Subjects With Localized T1-T2 Prostate Cancer in China Who Were Injected With SpaceOAR HydrogelUrinary, Bowel and Sexual Function Assessment ScoreSexual31 score on a scaleStandard Deviation 16.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026